Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03418857 · ClinicalTrials.gov registry record · Phase 1

Probiotics and Gut Health

A Phase 1 study of Metabolic Syndrome, sponsored by Penn State University.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT03418857: Recruiting Phase 1 study of Metabolic Syndrome, sponsored by Penn State University.

NCT03418857 is a Phase 1 study of Metabolic Syndrome that is actively recruiting participants, run by Penn State University. The registered enrollment target is 40 participants, below the 1,205-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03418857, a Phase 1 study of Metabolic Syndrome, is actively recruiting participants, sponsored by Penn State University.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This study evaluates the effects of probiotic consumption on inflammatory outcomes and measures of gut health. Participants will be given yogurt with probiotics for one period and yogurt without probiotics for another, with a break in between. These periods will occur in random order.

Primary Outcome

Change in inflammatory markers in the serum and secreted cytokines from lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells compared to baseline. In the serum the markers to be investigated are high sensitivity c-reactive protein (hs-CRP), tumor necrosis factor alpha (TNF-a), interleukin 1 beta (IL-1B), IL-6, IL-8, IL-10, IL-12p70, monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein alpha (MIP-1a), sCD14, and LPS binding protein (LPB). From LPS-stimulated p

Conditions Studied

Interventions

  • DRUG Yogurt smoothie with BB-12
  • DRUG Yogurt smoothie

Study Locations (1)

Pennsylvania

  • The Pennsylvania State University - University Park

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2018-06-29
Est. Completion 2022-12
Phase Phase 1
Penn State University

219 total trials

What NCT03418857 shows while recruiting

NCT03418857 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,205-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Metabolic Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Yogurt smoothie with BB-12 is the first listed.

NCT03418857 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03418857 about?

NCT03418857 is a clinical study titled "Probiotics and Gut Health". This study evaluates the effects of probiotic consumption on inflammatory outcomes and measures of gut health. Participants will be given yogurt with probiotics for one period and yogurt without probiotics for another, with a break in between. These periods will occur in random order.

What is the current status of trial NCT03418857?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-06-29. Estimated completion is 2022-12.

What conditions does trial NCT03418857 study?

This clinical trial studies the following conditions: Metabolic Syndrome.

What interventions are being tested in trial NCT03418857?

The interventions under investigation include: Yogurt smoothie with BB-12 (DRUG), Yogurt smoothie (DRUG).

Who is sponsoring clinical trial NCT03418857?

This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03418857 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metabolic Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03418857's enrollment target sits among peer trials

40 67th of 102 higher than 34 of 102 other Metabolic Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metabolic Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03418857, the US trial registry maintained by the National Library of Medicine. NCT03418857 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.